SG11201803001WA - Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation - Google Patents
Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparationInfo
- Publication number
- SG11201803001WA SG11201803001WA SG11201803001WA SG11201803001WA SG11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA SG 11201803001W A SG11201803001W A SG 11201803001WA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- affinity chromatography
- pharmaceutical preparation
- drug conjugate
- cyclic peptide
- Prior art date
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 238000001042 affinity chromatography Methods 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015209030 | 2015-10-23 | ||
PCT/JP2016/081353 WO2017069269A1 (fr) | 2015-10-23 | 2016-10-21 | Peptide cyclique, support de chromatographie d'affinité, anticorps marqué, conjugué anticorps-médicament et préparation pharmaceutique |
JP2016206753A JP6554452B2 (ja) | 2015-10-23 | 2016-10-21 | 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803001WA true SG11201803001WA (en) | 2018-05-30 |
Family
ID=58803678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803001WA SG11201803001WA (en) | 2015-10-23 | 2016-10-21 | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation |
Country Status (10)
Country | Link |
---|---|
US (1) | US10703778B2 (fr) |
EP (1) | EP3366693B1 (fr) |
JP (1) | JP6554452B2 (fr) |
KR (1) | KR102139057B1 (fr) |
CN (1) | CN108137651B (fr) |
AU (1) | AU2016340472B2 (fr) |
BR (1) | BR112018008117A2 (fr) |
CA (1) | CA3000979A1 (fr) |
RU (1) | RU2694050C1 (fr) |
SG (1) | SG11201803001WA (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201902818PA (en) * | 2016-09-30 | 2019-05-30 | Fujifilm Corp | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation |
WO2020075670A1 (fr) * | 2018-10-10 | 2020-04-16 | 国立大学法人鹿児島大学 | Peptide de liaison à l'igg comprenant un support en phase solide, et procédé de séparation d'igg |
BR112021023540A2 (pt) * | 2019-05-24 | 2022-03-22 | Avitide LLC | Agentes de afinidade |
JP7230197B2 (ja) * | 2019-06-11 | 2023-02-28 | 富士フイルム株式会社 | 環状ペプチド、細胞足場材、細胞分離材、及び、培地 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817752A (en) | 1996-06-06 | 1998-10-06 | La Jolla Pharmaceutical Company | Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
US6303576B1 (en) | 1999-04-21 | 2001-10-16 | Adherex Technologies Inc. | Compounds and methods for modulating β-catenin mediated gene expression |
EP1240337B1 (fr) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methodes et compositions permettant de prolonger les demi-vies d'elimination de composes bioactifs |
ES2292638T3 (es) * | 2000-11-08 | 2008-03-16 | Fresenius Medical Care Affina Gmbh | Peptidos, su preparacion y su uso para la union a inmunoglobulinas. |
CA2444680A1 (fr) | 2001-04-18 | 2002-10-31 | Dyax Corp. | Molecules de liaison pour les polypeptides de zone fc |
CA2456964A1 (fr) * | 2001-08-08 | 2003-02-20 | Merck & Co., Inc. | Antagonistes d'hormone concentrant la melanine |
KR20040087765A (ko) | 2003-04-09 | 2004-10-15 | 주식회사 일산 | 관체 성형방법 및 그 장치 |
WO2012040259A2 (fr) * | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Compstatine modifiée ayant des propriétés de stabilité et de liaison améliorées |
EP2749646B1 (fr) | 2011-08-24 | 2018-03-21 | Kagoshima University | Peptide de liaison à l'immunoglobuline g et procédé de détection et d'épuration d'immunoglobuline g mettant en oeuvre un tel peptide |
US9683018B2 (en) * | 2013-07-25 | 2017-06-20 | Novartis Ag | Disulfide cyclic polypeptides for the treatment of heart failure |
-
2016
- 2016-10-21 JP JP2016206753A patent/JP6554452B2/ja active Active
- 2016-10-21 SG SG11201803001WA patent/SG11201803001WA/en unknown
- 2016-10-21 RU RU2018114690A patent/RU2694050C1/ru active
- 2016-10-21 KR KR1020187009948A patent/KR102139057B1/ko active IP Right Grant
- 2016-10-21 CN CN201680061489.0A patent/CN108137651B/zh active Active
- 2016-10-21 AU AU2016340472A patent/AU2016340472B2/en active Active
- 2016-10-21 BR BR112018008117-5A patent/BR112018008117A2/pt not_active Application Discontinuation
- 2016-10-21 EP EP16857582.7A patent/EP3366693B1/fr active Active
- 2016-10-21 CA CA3000979A patent/CA3000979A1/fr active Pending
-
2018
- 2018-04-10 US US15/949,769 patent/US10703778B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2694050C1 (ru) | 2019-07-09 |
KR20180041243A (ko) | 2018-04-23 |
JP6554452B2 (ja) | 2019-07-31 |
EP3366693A4 (fr) | 2018-12-05 |
CN108137651B (zh) | 2022-02-22 |
AU2016340472A1 (en) | 2018-05-10 |
BR112018008117A2 (pt) | 2018-11-06 |
US20180230184A1 (en) | 2018-08-16 |
JP2017095443A (ja) | 2017-06-01 |
EP3366693B1 (fr) | 2023-08-16 |
KR102139057B1 (ko) | 2020-07-29 |
CA3000979A1 (fr) | 2017-04-27 |
AU2016340472B2 (en) | 2019-02-28 |
CN108137651A (zh) | 2018-06-08 |
US10703778B2 (en) | 2020-07-07 |
EP3366693A1 (fr) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263600B1 (en) | Antibodies against b7–h3 and drug-antibody conjugates | |
ZA201806576B (en) | Antibodies, pharmaceutical compositions and methods | |
EP3284751A4 (fr) | Anticorps anti-c-met, conjugué d'anticorps anti-c-met-médicament cytotoxique et leur utilisation pharmaceutique | |
SI3453707T1 (sl) | Benzazepinski derivati, postopek priprave, farmacevtski sestavek in uporaba le-teh | |
HK1255566A1 (zh) | 氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用 | |
IL291073A (en) | Drug conjugates of anti-egfr antibodies | |
IL267834A (en) | Conjugates of drug and antibody against CCR7 | |
IL254098B (en) | Compressed ring derivatives and method of preparation, intermediates, pharmaceutical preparations and their use | |
IL275798A (en) | Methods for antibody drug conjugation, purification and formulation | |
EP3250238A4 (fr) | Conjugués anticorps-médicament | |
EP3491026A4 (fr) | Anticorps humains, compositions pharmaceutiques et procédés | |
SG11202001647UA (en) | Conjugate of vegf-grab protein and drug, and use thereof | |
EP3253212A4 (fr) | Conjugués anticorps-médicament | |
SG11201803001WA (en) | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation | |
EP3411382A4 (fr) | Conjugué médicament-anticorps anti-egfr | |
EP3521300A4 (fr) | Peptide cyclique, support de chromatographie d'affinité, anticorps marqué, conjugué anticorps-médicament, et préparation pharmaceutique | |
EP3308801A4 (fr) | Conjugué anticorps-médicament, intermédiaire, procédé de préparation, compositions pharmaceutique et leurs utilisations | |
IL265645A (en) | Monoclonal cmet binding agents, their drug conjugates and uses thereof | |
IL272920A (en) | EGFR Antibody Drug Conjugates (ADC) and Their Uses | |
EP3476864A4 (fr) | Anticorps dirigé contre etar, composition pharmaceutique et utilisation associées | |
EP3675908A4 (fr) | Conjugués anticorps anti-egfr-médicament (adc) et utilisations associées | |
IL262929A (en) | Preparations for treatment, methods for their preparation and their uses | |
EP3599250A4 (fr) | Conjugué d'anticorps, composition pharmaceutique et application associées |